Abbott Laboratories stock pre-market at EUR 87.58: plus 0.03 percent
Published on 10/07/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock was at EUR 87.58 pre-market at Lang & Schwarz at 7:57 a.m. CEST on October 7, 2026, up 0.03 percent versus the Lang & Schwarz prior close of EUR 87.55 on October 6, 2026.
Pre-market trading
The Lang & Schwarz quote showed a bid of EUR 87.38 and an ask of EUR 87.78. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Abbott Laboratories stock.
FDA approval for CardioMEMS updates
In a PR Newswire release dated October 5, 2026, Abbott said the U.S. Food and Drug Administration approved updates to its CardioMEMS HF System. The changes allow care teams to let U.S. patients view pulmonary artery pressure readings through the CardioGuide HF App on their smartphones.
The release said the updated system also includes Dynamic Treatment Plan, a software feature that lets clinicians create personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan available later in 2026, according to the release.
